Enhancing the Standard of Care in Wet AMD, BRVO, & DME

Time: 9:45 am
day: Day One

Details:

  • Outlook Therapeutics is attempting to achieve the first FDA approval in ophthalmology for Bevacizumab
  • Outlook’s ONS 5010 meets standards required for FDA approval in ophthalmology not currently available by off label bevacizumab that is used on label for drip IV applications
  • Data from the pivitol trial for ONS 5010 were outstanding and highly statistically significant

Speakers: